Stay updated on OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedMany new recruitment sites were added across the US, Argentina, Australia, and numerous European and Asian countries, expanding the geographic availability of study sites. At the same time, a large number of existing locations were removed.SummaryDifference4%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed.SummaryDifference0.1%

- Check39 days agoChange DetectedRemoved the general operations notice about government funding; this is a minor change that does not affect study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedUpdated the trial site location name from Tainan City to Tainan (Taiwan, 736) in the Locations section.SummaryDifference0.0%

- Check53 days agoChange DetectedRemoved external health information links (MedlinePlus Genetics, MedlinePlus breast cancer, DailyMed, NIH/NIH.gov, and related resources) from the Study Details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check60 days agoChange DetectedAdded external information links to MedlinePlus genetics and breast cancer pages, DailyMed drug information for the therapies listed in the study, Olema publications, and U.S. government sites. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page.